Matthew J. Hoptman, Ph.D.

Hoptman

Matthew J. Hoptman, Ph.D.

Research Scientist
Clinical Research
845-398-6569
Hoptman

Dr. Matthew Hoptman, PhD, received his PhD from the University of Chicago in 1991 and completed a postdoctoral fellowship at University of Wisconsin – Madison with Richard J. Davidson on the neurocognitive and neurophysiology of healthy aging. Dr. Hoptman is a Research Scientist V and is a Research Associate Professor in the Department of Psychiatry at NYU Grossman School of Medicine. He is an experimental neuropsychologist and neuroimager who has been studying aggression and impulsivity for the past 20 years using multiple imaging methods, including MRI, EEG, and neuromodulation.

His work at NKI has focused on the role of circuit abnormalities in schizophrenia. In particular, he has focused on the neural correlates of impulsivity in schizophrenia using neuroimaging approaches. This work led to NIMH funded studies on the topic as well as on the relationship between functional and structural brain connectivity and cognitive and behavioral deficits in schizophrenia. His more recent work has focused specifically on the role of emotion-based impulsivity (urgency) on problem behaviors in schizophrenia. He recently completed an American Foundation for Suicide Prevention pilot grant to study the role of emotion regulation on suicidal ideation and behavior (SIB) in psychosis. In that study, he examined urgency and used an fMRI task of emotion regulation to assess abnormalities in the neural circuitry underlying these phenomena. Dr. Hoptman is currently planning to expand his work to a transdiagnostic study of urgency and SIB to depression. He also has an extensive history of work examining the neural basis of cognitive and emotional control deficits in late-life depression, as well as the role of olanzapine on structural and functional abnormalities in psychotic depression.

Dr. Hoptman serves as a frequent ad hoc reviewer for NIH Study Sections, and is an Associate Editor for Frontiers in Psychiatry and on the Editorial Board of Brain Sciences. He also serves as vice chair of the NKI Institutional Review Board, as well as being a member of NKI’s Action Against Racism Committee.

Select Publications

  • Hoptman MJ, Tural U, Arnold MS, Collins KA, Evans KT, Irvin MK, Parincu Z, Rette DN, Sparpana AM, Sullivan EF, Iosifescu DV. Suicidal ideation and behavior in schizophrenia: The role of negative urgency and psychiatric symptoms. Schizophr Res. 2023 Apr;254:173-175. doi: 10.1016/j.schres.2023.02.006. Epub 2023 Mar 10. PMID: 36906943.
  • Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Lerch JP, Flint AJ. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020 Jul 1;77(7):674-683. doi: 10.1001/jamapsychiatry.2020.0036. PMID: 32101271; PMCID: PMC7330722.
  • Hoptman MJ, Antonius D, Mauro CJ, Parker EM, Javitt DC. Cortical thinning, functional connectivity, and mood-related impulsivity in schizophrenia: relationship to aggressive attitudes and behavior. Am J Psychiatry. 2014 Sep;171(9):939-48. doi: 10.1176/appi.ajp.2014.13111553. PMID: 25073506; PMCID: PMC4178944.
  • Nolan KA, D’Angelo D, Hoptman MJ. Self-report and laboratory measures of impulsivity in patients with schizophrenia or schizoaffective disorder and healthy controls. Psychiatry Res. 2011 May 15;187(1-2):301-3. doi: 10.1016/j.psychres.2010.10.032. Epub 2010 Nov 23. PMID: 21106252; PMCID: PMC3075418.
  • Hoptman MJ, D’Angelo D, Catalano D, Mauro CJ, Shehzad ZE, Kelly AM, Castellanos FX, Javitt DC, Milham MP. Amygdalofrontal functional disconnectivity and aggression in schizophrenia. Schizophr Bull. 2010 Sep;36(5):1020-8. doi: 10.1093/schbul/sbp012. Epub 2009 Mar 30. PMID: 19336392; PMCID: PMC2930349.
  • Hoptman MJ, Yates KF, Patalinjug MB, Wack RC, Convit A. Clinical prediction of assaultive behavior among male psychiatric patients at a maximum-security forensic facility. Psychiatr Serv. 1999 Nov;50(11):1461-6. doi: 10.1176/ps.50.11.1461. PMID: 10543856.